Skip to content
Biodatica
Start free

Angiex, Inc.

CAMBRIDGE, MA · also filed as None

OncologyFormed
Compare Sign in to watch

What changed

Study registered, no phase assigned: Comparison of 5% Hypertonic Saline Versus 3% Hypertonic Saline in Resolution of Post-operative Corneal Edema.

8w agoTrial registeredMay 22, 2026Source filing (opens the source filing in a new tab)

Momentum

79no change

Momentum 79 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

~118months

The last disclosed raise still models out past a year.

Stage

Formed

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

17 pre-ticker oncology companies at Formed

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Filing

    Form D/A · $22M

    Sep 26, 2025

    Angiex, Inc. · private raise, self-reported by the issuer

    SEC EDGAR · 0001710380-25-000005 (opens the source filing in a new tab)

  2. Trial

    NA registered

    Jun 1, 2025

    Corneal Edema · COMPLETED · sponsor: Muhammad Aamir Latif · Comparison of 5% Hypertonic Saline Versus 3% Hypertonic Saline in Resolution of Post-operative Corneal Edema.

    ClinicalTrials.gov · NCT07605273 (opens the source filing in a new tab)

  3. Trial

    NA registered

    May 1, 2025

    Major Depressive Disorder (MDD), Cognitive Dysfunction · RECRUITING · sponsor: Portland VA Medical Center · Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

    ClinicalTrials.gov · NCT06728774 (opens the source filing in a new tab)

  4. Trial

    Study registered

    Aug 10, 2024

    Atherosclerosis and Blood Flow in Coronary Artery · RECRUITING · sponsor: Bangladesh University of Engineering and Technology · Geometrical Influences on Atherosclerosis and Blood Flow

    ClinicalTrials.gov · NCT07002697 (opens the source filing in a new tab)

  5. Grant

    P20 · $228k · non-dilutive

    Mar 1, 2021

    LOUISIANA STATE UNIV HSC SHREVEPORT · PI GUO, HONGYAN · NIGMS · award ends Jun 15, 2026 · Oncolytic Herpes Simplex Virus (HSV)1 as adjuvants for melanoma

    NIH RePORTER · NIH RePORTER 11128479 (opens the source filing in a new tab)

  6. Grant

    R01 · $387k · non-dilutive

    Mar 11, 2016

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GUO, HAITAO · NIAID · award ends Jun 30, 2027 · Molecular Mechanisms of HBV cccDNA Formation

    NIH RePORTER · NIH RePORTER 11122232 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources